Impact of daily number of urgency urinary incontinence episodes on overactive bladder patient reported outcomes

To explore the impact of urgency urinary incontinence (UUI) on well-being in non-institutionalized patients with overactive bladder (OAB) in a community sample.

A cross-sectional web-based study was conducted in the general population, including males and females, >18 years of age.

Patients with probable OAB were identified using a validated algorithm together with a score ≥8 on the OAB-V8 scale. Presence of coping behavior was considered determinant for the clinical diagnosis of OAB. Individual well-being was determined through a battery of patient-reported outcomes (PRO) measurements including assessment of health-related quality of life (EQ-5D), sleep disturbances (MOS Sleep), and life satisfaction (LISAT-8). Patients were grouped according to the number of daily UUI episodes (UUI severity): 0 (dry OAB),1, 2-3, or ≥4. Multivariate analysis to evaluate factors independently affecting quality of life was undertaken.

A total of 396 patients (52. 5% women, mean age: 55. 3 [11. 1] years, OAB-V8 mean score: 14. 5 [7. 9]) out of 2035 subjects participating from the general population met the criteria for OAB: 203 (51. 3%) with 0episodes, 119 (30. 1%) with 1, 52 (13. 1%) with 2 or 3, and 22 (5. 6%) with ≥4 episodes. A statistically significant linear adjusted association was found between number of UUI episodes and PRO scores. Participants with more episodes had poorer health profiles and self-evaluated quality of life, worse life satisfaction, and more sleep disturbances and fewer hours of sleep per night. Number of incontinence episodes was independent factor to affect quality of life using both LISAT-8 and MOS questionnaires.

Severity of UUI was significantly associated with poorer individual well-being in subjects with OAB in a community sample in Spain.

Actas urologicas espanolas. 2016 Jan 19 [Epub ahead of print]

J C Angulo, F J Brenes, I Lizarraga, J Rejas, S Trillo, D Ochayta, D Arumi

Servicio de Urología, Hospital Universitario de Getafe, Universidad Europea de Madrid, Laureate International Universities, Getafe, Madrid, España. Centro de Atención Primaria, Llefià, Badalona, España. , Unidad Médica, Pfizer S. L. U. , Alcobendas, Madrid, España. , Departamento de Investigación en Resultados y Economía de la Salud, Pfizer S. L. U. , Alcobendas, Madrid, España. , Unidad Médica, Pfizer S. L. U. , Alcobendas, Madrid, España. , oYs Integra, Madrid, España. , Unidad Médica, Pfizer Europe, Alcobendas, Madrid, España.

PubMed